{"brief_title": "Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions", "brief_summary": "Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.", "condition": "Prostate Cancer", "intervention_type": "Drug", "intervention_name": "zoledronic acid", "criteria": "Inclusion Criteria - Signed informed consent - Greater than 18 years of age - Proof of breast cancer, multiple myeloma or prostate cancer - Diagnosis of at least one cancer-related bone lesion - If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception - ECOG performance status of 0,1 or 2 - Ability to read, understand and write English or Spanish language - Normal renal function - Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria - clinically symptomatic brain metastases - hypersensitivity to Zometa or other bisphosphonates - pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00029224.xml"}